Apr 30, 2020
Biomarker Assessment and Targeted Treatment of Nonsquamous
Non-Small Cell Lung Cancer (NSCLC) — Slide Presentation 3: Optimal
Approach to Metastatic NSCLC with an EGFR Tumor Mutation After
Disease Progression on Osimertinib — Dr Wakelee.
CME information and select publications